Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 2
1988 1
1993 1
1994 3
1995 1
1996 1
1997 1
2000 1
2001 1
2003 1
2006 1
2007 3
2009 1
2010 3
2011 5
2012 2
2013 5
2014 7
2015 15
2016 17
2017 10
2018 10
2019 22
2020 21
2021 16
2022 14
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Malignant Testicular Germ Cell Tumor"
Page 1
European Association of Urology Guidelines on Testicular Cancer: 2023 Update.
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. Patrikidou A, et al. Eur Urol. 2023 Sep;84(3):289-301. doi: 10.1016/j.eururo.2023.04.010. Epub 2023 May 12. Eur Urol. 2023. PMID: 37183161 Review.
The key changes incorporated in the 2023 update include: new supporting text regarding venous thromboembolism prophylaxis in males with metastatic germ cell tumours receiving chemotherapy; quality of life after treatment; an update of the histological classifications and i …
The key changes incorporated in the 2023 update include: new supporting text regarding venous thromboembolism prophylaxis in males with m …
Management of testicular germ cell tumors.
Wee CE, Gilligan TD. Wee CE, et al. Clin Adv Hematol Oncol. 2023 Apr;21(4):179-188. Clin Adv Hematol Oncol. 2023. PMID: 37039725 Review.
Important remaining challenges include reducing the risk of secondary malignancies and other late effects of chemotherapy and radiation therapy, and developing curative treatments for patients with cancer that is refractory to current therapies. ...
Important remaining challenges include reducing the risk of secondary malignancies and other late effects of chemotherapy and …
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.
Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu B. Daneshmand S, et al. J Clin Oncol. 2023 Jun 1;41(16):3009-3018. doi: 10.1200/JCO.22.00624. Epub 2023 Mar 13. J Clin Oncol. 2023. PMID: 36913642 Clinical Trial.
Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors with minimal late morbidity although little data exist on its efficacy in early metastatic seminoma. Surgery in early metastatic seminoma is a prospective phase …
Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors with minimal late morbidity althou …
Prognostic factors in metastatic germ-cell cancer.
Beyer J. Beyer J. Andrology. 2019 Jul;7(4):475-478. doi: 10.1111/andr.12615. Epub 2019 Apr 10. Andrology. 2019. PMID: 30969027 Free article. Review.
Determining stage and anticipating prognosis are the two crucial steps after the diagnosis of a germ-cell cancer that both guide subsequent treatment decisions. This review focuses on metastatic disease, which means germ-cell cancers beyond stage I limited to the testis. I …
Determining stage and anticipating prognosis are the two crucial steps after the diagnosis of a germ-cell cancer that both guide subsequent …
Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship.
Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M, Frazier AL. Travis LB, et al. J Clin Oncol. 2024 Feb 20;42(6):696-706. doi: 10.1200/JCO.23.01099. Epub 2023 Oct 11. J Clin Oncol. 2024. PMID: 37820296 Review.
Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old men, and ovarian GCTs (OvGCTs) are the leading gynecologic malignancies in women younger than 25 years. Excellent outcomes, even in widely metastatic disease using cisplatin-based chemotherapy …
Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old men, and ovarian GCTs (OvGCTs) are the leading gynecologic mali …
Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W, Seidel C, Bokemeyer C, Oing C. Alsdorf W, et al. Expert Opin Pharmacother. 2019 May;20(7):837-850. doi: 10.1080/14656566.2019.1583745. Epub 2019 Mar 8. Expert Opin Pharmacother. 2019. PMID: 30849243 Review.
INTRODUCTION: With the implementation of platinum-based chemotherapy, germ cell tumors (GCTs) became a model for a curable solid tumor, with survival rates of 95% in all patients with >80% survival in metastatic stages. AREAS COVERED: Herein, the authors review the curr …
INTRODUCTION: With the implementation of platinum-based chemotherapy, germ cell tumors (GCTs) became a model for a curable solid tumor, with …
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.
Urbini M, Bleve S, Schepisi G, Menna C, Gurioli G, Gianni C, De Giorgi U. Urbini M, et al. Int J Mol Sci. 2023 Nov 28;24(23):16872. doi: 10.3390/ijms242316872. Int J Mol Sci. 2023. PMID: 38069192 Free PMC article. Review.
The outcome of metastatic testicular germ cell tumor patients has been dramatically improved by cisplatin-based chemotherapy combinations. ...
The outcome of metastatic testicular germ cell tumor patients has been dramatically improved by cisplatin …
Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Semaan A, et al. Future Oncol. 2019 Feb;15(5):533-541. doi: 10.2217/fon-2018-0571. Epub 2019 Jan 9. Future Oncol. 2019. PMID: 30624089 Review.
Testicular germ cell tumors are chemosensitive with very high cure-rates even in the metastatic setting. However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite salvage treatments, and with no ef …
Testicular germ cell tumors are chemosensitive with very high cure-rates even in the metastatic setting. However, patients with plati …
Testicular germ cell tumors: pathogenesis, diagnosis and treatment.
Winter C, Albers P. Winter C, et al. Nat Rev Endocrinol. 2011 Jan;7(1):43-53. doi: 10.1038/nrendo.2010.196. Epub 2010 Nov 30. Nat Rev Endocrinol. 2011. PMID: 21116298 Review.
Testicular germ cell tumors represent the most common solid malignancy of young men aged 15-40 years. Histopathologically, testicular germ cell tumors are divided into two major groups: pure seminoma and nonseminoma. The pathogenesis of testicular germ cell tumors remains …
Testicular germ cell tumors represent the most common solid malignancy of young men aged 15-40 years. Histopathologically, testicular …
Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C, Seidel C, von Amsberg G, Oechsle K, Bokemeyer C. Oing C, et al. Expert Opin Pharmacother. 2016;17(4):545-60. doi: 10.1517/14656566.2016.1127357. Epub 2015 Dec 31. Expert Opin Pharmacother. 2016. PMID: 26630452 Review.
INTRODUCTION: Testicular germ cell tumors are the most common malignancy among men aged 40 and less. Since the introduction of cisplatin-based combination chemotherapy, germ cell tumors are among the most curable solid tumors with cure rates of 95% in all patients and > …
INTRODUCTION: Testicular germ cell tumors are the most common malignancy among men aged 40 and less. Since the introduction of cispla …
163 results